Showing 1361-1370 of 1395 results for "".
- Study Demonstrates Long-Term IOP Reduction with the OMNI Surgical System Predicate Device (TRAB 360) in MIGShttps://modernod.com/news/clinical-study-demonstrates-long-term-iop-reduction-with-the-omni-surgical-system-predicate-device-trab-360-in-migs/2476378/A new, single-center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI Surgical System’s Predicate Devices (TRAB 360)
- Study Results Show NeurOptics’ NPi-200 Pupillometer Provides Early Warning of Neurological Damagehttps://modernod.com/news/study-results-show-neuroptics-npi-200-pupillometer-provides-early-warning-of-neurological-damage/2476358/A new study found that NeurOptics’ NPi-200 Pupillometer, which provides an automated assessment of the pupillary light reflex, may signal an early warning of potential delayed cerebral ischemia and enable preemptive escalation of care. The study was published in the Journal of Neurosurgery
- Raindrop Near Vision Inlay Recalledhttps://modernod.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/A Class I recall of the Raindrop near vision inlay has been issued due to an increased risk of corneal haze, according to the FDA. The owner of the Raindrop inlay, RVO 2.0, doing business as Optics Medical, issued the recall after an October warning letter from the FDA cited a post-approva
- Allergan Responds to Public Shareholder Letterhttps://modernod.com/news/allergan-responds-to-public-shareholder-letter/2476274/Allergan issued the following statement from its Board of Directors in response to a public shareholder letter from Appaloosa hedge fund manager David Tepper earlier this week that stated the drugmaker should consider a merger or selling itself if it is “unable or unwilling to hold manageme
- RightEye Introduces Functional Vision EyeQ Automated Testhttps://modernod.com/news/righteye-introduces-functional-vision-eyeq-automated-test/2476278/RightEye announced the launch of Functional Vision EyeQ, a first-of-its kind automated test that allows optometrists to quickly and objectively identify functional vision issues that affect a host of everyday activiti
- Heidelberg OCT2 Module Successfully Installed at the International Space Stationhttps://modernod.com/news/heidelberg-oct2-module-successfully-installed-at-the-international-space-station/2476295/Heidelberg Engineering announced that its Spectralis imaging platform with the company’s next-generation OCT2 Module has been successfully installed at the International Space Station (ISS) and is now fully operational. NASA launched the Spectralis with OCT2 Module to the ISS aboard the An
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16
- Retreatment With A Single TearCare Treatment Continues To Provide Relief For Patients With Dry Eye Diseasehttps://modernod.com/news/retreatment-with-a-single-tearcare-treatment-continues-to-provide-relief-for-patients-with-dry-eye-disease/2476302/A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release. The
- Bausch + Lomb Announces Health Canada Approval Of Vyzulta for the Treatment of Glaucomahttps://modernod.com/news/bausch-lomb-announces-health-canada-approval-of-vyzulta-for-the-treatment-of-glaucoma/2476223/Bausch + Lomb announced that Health Canada issued a Notice of Compliance approving Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Vyzulta is the first prostaglandin analog with one of its metabolites
- Diet Soda Linked to Increased Risk for Diabetic Retinopathyhttps://modernod.com/news/diet-soda-linked-to-increased-risk-for-diabetic-retinopathy/2476232/Drinking diet soda may increase the risk for proliferative diabetic retinopathy, according to a study published online in the September/October issue of Clinical and Experimental Ophthalmology, as